Celularity Stock Today
| CELU Stock | USD 1.55 0.01 0.65% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Celularity is selling for under 1.55 as of the 17th of March 2025; that is 0.65 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.52. Celularity has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of August 2019 | Category Healthcare | Classification Health Care |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. The company has 23.81 M outstanding shares of which 287.43 K shares are currently shorted by private and institutional investors with about 5.08 trading days to cover. More on Celularity
Moving together with Celularity Stock
| 0.61 | ENVB | Enveric Biosciences Earnings Call This Week | PairCorr |
Moving against Celularity Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Celularity Stock Highlights
| President Diseases | Stephen DPM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCelularity can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Celularity's financial leverage. It provides some insight into what part of Celularity's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celularity (CELU) is traded on NASDAQ Exchange in USA. It is located in 170 Park Avenue, Florham Park, NJ, United States, 07932 and employs 120 people. Celularity is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.9 M. Celularity conducts business under Biotechnology sector and is part of Health Care industry. The entity has 23.81 M outstanding shares of which 287.43 K shares are currently shorted by private and institutional investors with about 5.08 trading days to cover.
Celularity currently holds about 42.65 M in cash with (38.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Check Celularity Probability Of Bankruptcy
Ownership AllocationCelularity holds a total of 23.81 Million outstanding shares. Celularity retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Celularity Ownership Details
Celularity Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Centerstar Asset Management, Llc | 2024-12-31 | 22 K | |
| Ipg Investment Advisors, Llc | 2024-12-31 | 17.2 K | |
| Renaissance Technologies Corp | 2024-12-31 | 11 K | |
| Ground Swell Capital, Llc | 2024-12-31 | 10.5 K | |
| Bank Of America Corp | 2024-12-31 | 2.3 K | |
| Simplex Trading, Llc | 2024-12-31 | 1.5 K | |
| Ubs Group Ag | 2024-12-31 | 1.2 K | |
| Ifp Advisors, Llc | 2024-12-31 | 1000 | |
| Corecap Advisors, Llc | 2024-12-31 | 500 | |
| C V Starr & Co Inc | 2024-12-31 | 764.1 K | |
| Vanguard Group Inc | 2024-12-31 | 500.1 K |
Celularity Historical Income Statement
Celularity Stock Against Markets
Celularity Corporate Management
| Carlos Ramirez | SVP Relations | Profile | |
| Sharmila MD | Senior Safety | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Tim Wilk | Senior Operations | Profile | |
| Ramji Krishnan | Chief Officer | Profile | |
| Bradley Glover | Ex COO | Profile | |
| CPA MS | Treasurer | Profile |
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.